Danish multinational pharmaceutical company manufacturing and marketing products primarily focused on diabetes and obesity medications; formed through a 1989 merger of two Danish companies with origins tracing to the 1920s.
Clinical Trials
2776
1315 active
Approvals
405
Total approvals
Agencies
6
Regulatory bodies
Founded
1923
Terminated
43
1.6%
Recruiting
161
5.8%
Available
1
0.0%
Withdrawn
23
0.8%
Active, not recruiting
1280
46.1%
Unknown
7
0.3%
Completed
1226
44.2%
Enrolling By Invitation
20
0.7%
Not yet recruiting
15
0.5%
- The EMA's CHMP recommended 12 new medicines for approval at its September 14-17, 2026 meeting, alongside 11 therapeutic indication extensions and two biosimilars. - Povofortay (povorcitinib) became the first oral daily treatment recommended for adults with moderate to severe hidradenitis suppurativa refractory or intolerant to anti-TNF therapy. - Johnson & Johnson's Tecvayli (teclistamab) won support for earlier-line multiple myeloma use, with MajesTEC-3 data showing a 71% reduction in progression risk versus standard of care. - Two initial marketing applications were withdrawn, for apitegromab in 5q spinal muscular atrophy and trilaciclib in extensive-stage small-cell lung cancer, while three negative opinions entered re-examination.
- Ventus Therapeutics has dosed the first patient in a Phase 2 clinical trial of VENT-03, marking the most advanced oral small-molecule cGAS inhibitor in clinical development. - The multicenter, randomized, double-blind, placebo-controlled trial will evaluate VENT-03's efficacy and safety in lupus patients with active skin disease, targeting more than five million people living with lupus worldwide. - The study incorporates biomarkers for inflammation and cardiovascular health, with top-line results expected in the second half of 2026 from the 28-day placebo-controlled portion. - VENT-03 represents a first-in-class approach targeting the cGAS pathway, which plays a key role in inflammation and has been implicated in multiple autoimmune diseases and cardiometabolic disorders.
- The Full Court of the Federal Court of Australia ruled that only patents claiming active pharmaceutical ingredients are eligible for patent term extensions, not pharmaceutical formulations. - The decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd invalidates existing patent term extensions for formulation patents, creating "zombie PTEs" vulnerable to challenge. - Pharmaceutical companies must urgently review their patent portfolios as the ruling affects loss of exclusivity dates and may accelerate generic drug market entry across Australia.
- Ventus Therapeutics announced a multi-year collaboration with Genentech to discover novel small-molecule candidates using its proprietary ReSOLVE® platform, which combines AI, machine learning, and biophysics. - The agreement includes an upfront payment and potential milestones exceeding $460 million plus tiered royalties, with Ventus handling virtual screening and Genentech managing development and commercialization. - ReSOLVE® uniquely models dynamic water networks in protein pockets to accelerate drug discovery, offering a computational approach to tackle challenging therapeutic targets across multiple disease areas.
- DelveInsight's 2025 pipeline report reveals a robust obesity therapeutics landscape with over 80 companies developing more than 100 pipeline drugs across various clinical stages. - Major pharmaceutical companies including Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Carmot Therapeutics are advancing multiple Phase II and III trials scheduled for February 2025. - Leading drug candidates include survodutide (Zealand Pharma/Boehringer Ingelheim), a dual GLP-1/glucagon receptor agonist in Phase III trials, and CT-868 (Carmot Therapeutics), a dual GLP-1/GIP receptor modulator in Phase II development. - The pipeline encompasses diverse therapeutic approaches including dual hormone receptor agonists, combination therapies, and novel mechanisms targeting different molecular pathways for weight management.
- DelveInsight's 2025 report reveals over 200 companies are actively developing more than 200 pipeline therapies for diabetes treatment, indicating a highly competitive and innovative landscape. - Several promising late-stage candidates are advancing through Phase III trials, including Cadisegliatin (vTv Therapeutics) for type 1 diabetes and Insulin efsitora alfa (Eli Lilly) as a once-weekly basal insulin. - Recent clinical trial announcements from major pharmaceutical companies demonstrate continued investment in diabetes research, with studies comparing novel formulations and combination therapies. - The pipeline encompasses diverse therapeutic approaches including liver-selective glucokinase activators, ultra-rapid-acting insulin analogs, and oral GLP-1 receptor agonists targeting different aspects of diabetes management.
• The GLP-1 agonists market is projected to experience substantial growth by 2034, driven by increased awareness and efficacy in managing diabetes and obesity. • Key players like Novo Nordisk, AstraZeneca, and Viking Therapeutics are developing innovative GLP-1 agonists, including oral formulations, to enhance patient adherence. • Emerging therapies such as VK2735, TERN-601, and ECC5004 are poised to transform the market with improved efficacy and novel mechanisms of action. • GLP-1 agonists are gaining traction beyond diabetes, showing promise in treating obesity and non-alcoholic fatty liver disease (NAFLD), expanding their therapeutic potential.
• The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. • This growth is fueled by the introduction of novel therapies targeting NASH, with several drugs in Phase II and Phase III clinical trials showing promise for improving treatment outcomes. • Key players such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Novo Nordisk are actively developing innovative treatments, contributing to a dynamic and competitive market landscape. • The increasing prevalence of NASH and the growing understanding of its pathophysiology are driving the demand for effective therapies, creating opportunities for pharmaceutical companies.
• The omics-based clinical trials market is projected to reach USD 70.92 billion by 2034, driven by the increasing adoption of personalized medicine. • Phase III trials currently dominate the market due to their large participant numbers and high costs, while Phase I trials are expected to grow fastest. • Oncology leads the market by indication, fueled by the rising prevalence of cancer and the need for more effective treatment strategies. • North America currently holds the largest market share, supported by favorable regulatory frameworks and a growing emphasis on personalized medicine.
• The omics-based clinical trials market is projected to reach USD 70.92 billion by 2034, driven by the increasing adoption of personalized medicine. • Phase III trials currently dominate the market due to their large participant numbers and high costs, while Phase I trials are expected to grow fastest. • Oncology leads the market by indication, fueled by the rising prevalence of cancer and the need for more effective treatment strategies. • North America currently holds the largest market share, supported by favorable regulatory frameworks and a growing emphasis on personalized medicine.
